Clinical Trial Update: Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal [Phase 2]

View source ↗

Summary

Phase 2 trial assessing VIUSID® Plus GLIZIGEN® for papillomavirus-related esophageal conditions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Verrucous Carcinoma
• Esophageal Viral Wart
• Papillomavirus Infections

Drugs mentioned

• VIUSID® Plus GLIZIGEN®

Snippet

Sponsor: Catalysis SL | Conditions: Papilloma Viral Infection, Papillomavirus Infections | Phase 2 | Status: COMPLETED